MIM
MIST icon

Monashee Investment Management’s Milestone Pharmaceuticals MIST Stock Holding History

Monashee Investment Management’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-500,000
Closed -$895K – 108
2024
Q1 		$895K Buy
+500,000
New +$812K 0.11% 93

Other funds holding MIST

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $265M AUM 98.61% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Monashee Investment Management's MIST Position: Q2 2024 in Review

Monashee Investment Management sold out of Milestone Pharmaceuticals (MIST) in Q2 2024, closing a stake of 500,000 shares — an estimated $895K sold.

Monashee Investment Management first reported a position in MIST in Q1 2024 and held it in 1 quarter. The position peaked at $895K in Q1 2024. 40 funds tracked by Wall St. Rank hold MIST as of Q2 2024.

  • Monashee Investment Management reported no remaining Milestone Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Monashee Investment Management sold 500,000 Milestone Pharmaceuticals shares in Q2 2024, an estimated $895K.
  • Monashee Investment Management first reported a position in Milestone Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Monashee Investment Management's Milestone Pharmaceuticals position peaked at $895K in Q1 2024.
  • 40 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2024.

Based on Monashee Investment Management's 13F filing for Q2 2024, filed 12 Aug 2024.